AstraZeneca’s Farxiga Flies Across $1bn Barrier

Stellar Sales Of SGLT2 Inhibitor

29 Apr 2022

First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.

While much of the focus on AstraZeneca PLC's first-quarter figures was on its COVID-19 products Vaxzevria and Evusheld, the drug that caught the eye was Farxiga, hitting the $1bn sales mark and exceeding analyst forecasts by some distance.

Speaking to Scrip as AstraZeneca unveiled a healthy set of financials for the first quarter which saw sales jump 56% to $11.39bn, CEO Pascal Soriot said that Farxiga/Forxiga (dapagliflozin) was "a fantastic medicine and not only for patients with diabetes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

09 May 2025

• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

09 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.